Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cobicistat + Revumenib |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cobicistat | Tybost | GS 9350|Evotaz|Genvoya|Prezcobix|Rezolsta|Stribild | Tybost (cobicistat) is an inhibitor of human cytochrome P450 3A (CYP3A), which potentially enhances exposure to other co-administered drugs (PMID: 24900196, PMID: 35933915). Tybost (cobicistat) is FDA approved to increase systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the treatment of HIV-1 infection (FDA.gov). | |
| Revumenib | Revuforj | SNDX5613|SNDX 5613|SNDX-5613 | MEN1-KMT2A Inhibitor 8 | Revuforj (revumenib) inhibits the interaction between Menin and KMT2A (MLL), potentially resulting in antitumor activity and decreased proliferation of tumor cells with KMT2A (MLL) rearrangements or NPM1 mutations (PMID: 36922593, PMID: 36922589). Revuforj (revumenib) is FDA-approved for use in adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia harboring KMT2A translocation, and in adult and pediatric patients 1 year and older with relapsed or refractory acute myeloid leukemia harboring susceptible NPM1 mutations (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|